ESA推出检测血铅含量的新系统
一种检测血液中铅含量的系统设计用于儿科医生、家庭开业者、公共健康保健系统和军队诊所。该检测项目将在7月25-27日芝加哥(Il, USA)举行的美国临床生化年会(AACC)临床检验博览会上投放市场。
ESA生物科学公司(Chelmsford, MA, USA)是Magellan生物科学公司的分支机构，将LeadCare II引入该公司获得了CLIA(临床实验室改善管理)豁免资格。LeadCare II是ESA公司原来LeadCare系统的改进版。豁免资格将会扩大扩大那些潜在的结构，从而使得这些机构能够检测血铅:例如在医生办公室、社区保健中心、WIC(妇女、婴儿和儿童)工程和流动诊所、保健系统、或者家庭访问，从而为健康保健系统提供了对最可能面临铅中毒危险的儿童和成人进行检测的新工具。
New System for Detecting Lead in Blood
A new system for testing lead in blood is designed for use by pediatricians, family practitioners, public health systems, and military clinics. The test is to be launched at the Clinical Lab Expo at the annual meeting of the American Association for Clinical Chemistry (AACC), July 25-27, in Chicago (Il, USA).
ESA Biosciences Inc. (Chelmsford, MA, USA), a subsidiary of Magellan Biosciences, will introduce LeadCare II providing the company receives CLIA (Clinical Laboratory Improvement Management)-waiver status. LeadCare II is an improved version of ESA’s original LeadCare system. Waived status will expand the potential sites where lead testing can be performed: for example, in physician’s offices, community health centers, WIC (women, infant, and children) programs, and mobile clinics, health fairs, or home visits, thereby giving healthcare providers a new tool to reach those children and adults most at risk for lead poisoning.